Questcor to Report First Quarter Results on April 30, 2013
ANAHEIM, Calif., April 15, 2013
ANAHEIM, Calif., April 15, 2013 /PRNewswire/ --Questcor Pharmaceuticals, Inc.
(NASDAQ: QCOR) today announced that it will release first quarter 2013
financial results on Tuesday, April 30, 2013 after the close of the U.S.
financial markets. The Company will host a conference call and slide
presentation via webcast on Tuesday, April 30, 2013 at 4:30 p.m. Eastern /
1:30 p.m. Pacific to discuss results and highlights of the quarter, as well as
current corporate developments.
The call can be accessed in the following ways:
oBy webcast: At Questcor's investor relations website,
oBy telephone: For both "listen-only" participants and those participants
who wish to take part in the question-and-answer portion of the call, the
dial-in number in the U.S. is (877) 354-0215. For participants outside the
U.S., the dial-in number is (253) 237-1173.
oBy audio replay: A replay of the conference call will be available for
seven business days following conclusion of the live call. The telephone
dial-in number for U.S. participants is (855) 859-2056. For participants
outside the U.S., the replay dial-in number is (404) 537-3406. The replay
access code for all callers is 34200996.
Questcor Pharmaceuticals, Inc. is a biopharmaceutical company focused on the
treatment of patients with serious, difficult-to-treat autoimmune and
inflammatory disorders. Questcor also provides specialty contract
manufacturing services to the global pharmaceutical industry through its
wholly-owned subsidiary BioVectra Inc. Questcor's primary product is H.P.
Acthar® Gel (repository corticotropin injection), an injectable drug that is
approved by the FDA for the treatment of 19 indications. Of these 19
indications, Questcor currently generates substantially all of its net sales
from the following on-label indications: the treatment of proteinuria in the
nephrotic syndrome of the idiopathic type, or NS, the treatment of acute
exacerbations of multiple sclerosis, or MS, in adults, the treatment of
infantile spasms, or IS, in infants and children under two years of age, and
the treatment of certain rheumatology related conditions, including the
treatment of the rare and closely related neuromuscular disorders
dermatomyositis and polymyositis. With respect to nephrotic syndrome, the FDA
has approved Acthar to "induce a diuresis or a remission of proteinuria in the
nephrotic syndrome without uremia of the idiopathic type or that due to lupus
erythematosus. Questcor is also exploring the possibility of developing
markets for other on-label indications and the possibility of pursuing FDA
approval of additional indications not currently on the Acthar label where
there is high unmet medical need. For more information about Questcor, please
SOURCE Questcor Pharmaceuticals, Inc.
Contact: Gregory Gin, +1-646-445-4801, or Patty Eisenhaur, +1-951-316-0577,
EVC Group, or Doug Sherk, +1-415-652-9100, or Janine McCargo, +1-646-688-0425
Press spacebar to pause and continue. Press esc to stop.